168 articles with Flexion Therapeutics
12/23/2019Heading into the holidays, there was still plenty of clinical trial news last week. Here’s a look.
Flexion Therapeutics Enrolls First Patients in Phase 2 Trial of ZILRETTA® (triamcinolone acetonide extended-release injectable suspension) in OA of the Shoulder and Adhesive Capsulitis
Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced that the first three patients were enrolled in a clinical trial to evaluate the efficacy of ZILRETTA (triamcinolone acetonide extended-release injectable suspension) in patients with either shoulder osteoarthritis (OA) or adhesive capsulitis (AC), also known as frozen shoulder.
Flexion Therapeutics Announces the Retirement of Neil Bodick, M.D., Ph.D., Chief Scientific Officer and Company Co-Founder
Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced that Neil Bodick, M.D., Ph.D., Chief Scientific Officer, will retire effective January 3, 2020.
Flexion Therapeutics to Host Physician Event at Orthopaedic Summit 2019 Featuring Panel of Former Professional Athletes Treated With ZILRETTA® for Osteoarthritis Knee Pain
Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced the speaker lineup for a “Spotlight Session” the company is hosting at the Orthopaedic Summit 2019: Evolving Techniques (OSET 2019) annual meeting in Las Vegas
Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced equity inducement grants to six new employees consisting of an aggregate of 25,300 stock options and 4,150 restricted stock units.
11/18/2019It was a busy week for clinical trial announcements. Here’s a look.
Flexion Therapeutics Presents ZILRETTA® (triamcinolone acetonide extended-release injectable suspension) Efficacy Data at the AAHKS and ACR Annual Meetings
Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced results from a sensitivity analysis evaluating the treatment effects of a single administration of ZILRETTA (triamcinolone acetonide extended-release injectable suspension) in patients with moderate-to-severe osteoarthritis (OA) pain on both the Average Daily Pain (ADP) and WOMAC-A1 (pain) scales
Company reported ZILRETTA® (triamcinolone acetonide extended-release injectable suspension) net sales of $21.8 million in Q3 representing 29% growth over Q2
11/4/2019Even clinical trial announcements don’t slow down for Halloween. It was a typically busy week. Here’s a look.
Flexion Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) of November 1, 2019
Flexion Therapeutics, Inc. announced equity inducement grants to four new employees consisting of an aggregate of 14,700 stock options and 2,500 restricted stock units.
Flexion’s management will host a conference call at 4:30 p.m. ET to discuss the results and provide an update on business operations.
Flexion Therapeutics Announces FDA Clearance of the Investigational New Drug Application for FX201, a Gene Therapy Candidate for the Treatment of Osteoarthritis
In addressing a highly prevalent, non-monogenic musculoskeletal disease, FX201 has the potential to open a new treatment avenue for gene therapy
Flexion Therapeutics Announces Extended FDA Review of Supplemental New Drug Application for ZILRETTA®
Flexion Therapeutics, Inc. announced that the U.S. Food and Drug Administration has informed the company it needs additional time to complete the review of the supplemental New Drug Application for ZILRETTA The anticipated Prescription Drug User Fee Act action date was today, October 14, 2019..
There are several scheduled PDFUA dates for the U.S. Food and Drug Administration over the next two weeks. Here’s a look.
Flexion Therapeutics Sponsors a Memorial to the Victims of the Opioid Crisis to Raise Awareness of the Tragic Consequences of the Opioid Epidemic Across the U.S.
Flexion Therapeutics, Inc. announced its sponsorship of “Prescribed to Death: A Memorial to the Victims of the Opioid Crisis.” The national traveling exhibit is dedicated to building awareness of the continuing opioid crisis in the United States and was developed by the National Safety Council (NSC) as part of the Stop Everyday Killers public education campaign.
Flexion Therapeutics and Xenon Pharmaceuticals Announce Flexion’s Acquisition of an Investigational NaV1.7 Inhibitor for the Treatment of Post-Operative Pain
Flexion Therapeutics, Inc. and Xenon Pharmaceuticals Inc. announced that the companies have entered into a definitive agreement that provides Flexion with the global rights to develop and commercialize XEN402, a NaV1.7 inhibitor, for the management of post-operative pain.
There have been a number of leadership changes in biotech companies over the last week. BioSpace has put together a list of new c-suite level hires and position changes.
The stock options have an exercise price of $22.31 per share and were granted as inducements material to the employees entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4).
A look at six biopharma companies that may have major stock catalysts this year.
Flexion Therapeutics Announces Initial Data from Clinical Trial Evaluating Repeat Administration of ZILRETTA (Triamcinolone Acetonide Extended-Release Injectable Suspension)
Data show that 95% of patients achieved clinical benefit after a single administration of ZILRETTA.